Clinical trial · Interventional
Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms
A Randomized Exploratory Basket Study to Evaluate the Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms in Adult Participants With a Primary Non-DSM-5 Diagnosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CT-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Mild Cognitive Impairment | — | UNRESOLVED | — |
| Multiple Sclerosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Care-as-Usual | Other | — | UNRESOLVED |
| CT-100 DiNaMo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- ACTIVE_COMPARATOR
- label
- CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis
- description
- Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis
- interventionNames
- Other: CT-100 DiNaMo
- type
- SHAM_COMPARATOR
- label
- Care-as-Usual control in Patients with Multiple Sclerosis
- description
- Randomized controlled Study to Evaluate Care-as-Usual control in Patients with Multiple Sclerosis
- interventionNames
- Other: Care-as-Usual
- type
- ACTIVE_COMPARATOR
- label
- CT-100 DiNaMo (Study App) in Patients with Breast or Lung Cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 22 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: A participant will be eligible for entry into the study if all the following criteria are met: 1. Age ranges in years: 22-52 for Multiple Sclerosis, 35-65 for Cancer (Breast or Lung), and 45-75 for Mild Cognitive Impairment. 2. Diagnosis of indication under study (Multiple Sclerosis, Cancer - Breast or Lung, Mild Cognitive Impairment) 3. Self-reported cognitive impairment and mood symptoms that began in the context of the primary indication under study. 4. Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form.) 5. Willing and able to comply with study protocol and assessments, evidenced by completion of the Screening Survey. 6. Lives in the United States. 7. Has an active email address and is willing and able to receive email messages. 8. Is the sole user of an iPhone or a smartphone with an Android operating system, and with cellular and/or internet access for the duration of the study period. Exclusion Criteria: A participant is excluded from the study if any of the following criteria apply: 1. Physician-diagnosed insomnia in the Screening Survey. 2. Cognitive impairment/mood symptoms or clinical diagnosis of depression attributed to a condition other than the underlying medical condition. 3. Is currently pregnant or breastfeeding. 4. Substance use disorder within the past 1 year. 5. Initiation or change in central nervous system-active medication (e.g., antidepressants) during the last 2 months. 6. Participation in a clinical trial within the last 3 months. 7. Anticipates a lifestyle change or change in current treatment during the study period that could affect cognitive functioning. 8. Visual, dexterity or cognitive deficit so severe that precludes the use of an app. 9. Severe neurological disorders impairing brain function. 10. Psychiatric hospitalization in the past 6 months.
References
Publications (0)
Data not yet available